2-Methacryloyloxyethyl phosphorylcholine:Exports & Compliance White Paper 2026

I. Executive Summary

2-Methacryloyloxyethyl phosphorylcholine (MPC), CAS 67881-98-5, is a zwitterionic methacrylate monomer designed to reproduce the phosphorylcholine head-group environment found at the outer surface of cell membranes. Polymerized MPC creates strongly hydrated interfaces that can reduce nonspecific protein adsorption, cell adhesion and friction. These functions make the monomer strategically important in contact lenses, catheter and guidewire coatings, drug-eluting stent systems, blood-contacting devices, wound dressings, hydrogels and other engineered biomaterials.

Commercial success depends on more than nominal HPLC purity. MPC is extremely hygroscopic, and its methacrylate group can self-polymerize after heat, light, oxygen imbalance or depletion of inhibitor. Buyers should therefore define water, residual starting materials, phosphorus-containing impurities, color, assay, inhibitor identity and level, and storage history as critical quality attributes. Medical-device development also requires bioburden and endotoxin strategies, change control, extractables data and traceable manufacturing, none of which is established by a research-grade certificate alone.

The 2026 market is bifurcating between research reagent supply and application-qualified biomaterial supply. Device sponsors increasingly expect ISO 13485-compatible controls, support for ISO 10993 biological evaluation, FDA device master file access where appropriate, and EU MDR documentation. MPC itself is not a finished medical device and this paper makes no clinical or medical claim. Procurement decisions must be tied to the intended polymer, processing conditions, contact category and jurisdiction, with regulatory status and SDS classification confirmed before each shipment.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

MPC has formula C11H22NO6P and molecular weight 295.27. Its internal phosphate anion and trimethylammonium cation give high polarity and strong hydration, while the methacrylate double bond enables radical copolymerization. Commercial material is commonly a white to almost-white powder or crystalline solid. Literature and supplier data report a melting range near 143–148 °C, but thermal exposure is inappropriate for routine storage because polymerization risk is the practical constraint.

• Cell-membrane-mimetic hydration: The phosphorylcholine side chain binds a dense water shell without carrying a net charge. In a properly designed copolymer or grafted layer, this hydration barrier limits direct approach by proteins and cells. Performance depends on MPC surface density, polymer architecture, substrate anchoring, sterilization and ageing; monomer identity alone does not guarantee hemocompatibility.
• Reactive and moisture-sensitive monomer: The terminal methacrylate supports free-radical, controlled-radical and photopolymerization processes. The same functionality creates self-polymerization risk, while the zwitterionic head group readily absorbs atmospheric moisture. Water changes effective solids content and polymerization behavior, so Karl Fischer results and inhibitor concentration should accompany assay and identity data.

2.2 Synthesis and Manufacturing Technologies

A widely used route class builds a polymerizable cyclic phosphate ester and then introduces the choline functionality. Industrial execution requires anhydrous handling, controlled heat removal and careful removal of ionic by-products. Process development must balance conversion against premature methacrylate polymerization and should define hold times, inhibitor management and oxygen or nitrogen conditions through isolation and drying.

• Cyclic phosphate installation: 2-Hydroxyethyl methacrylate is phosphorylated with 2-chloro-2-oxo-1,3,2-dioxaphospholane under controlled, dry conditions to form a methacrylate-bearing cyclic phosphate intermediate. Temperature, base, feed profile and chloride removal influence residual HEMA, oligomer formation and phosphorus-species distribution. Closed processing is favored because the intermediates are moisture reactive and acid residues can impair color and stability.
• Trimethylamine ring opening and polishing: Trimethylamine opens the five-membered phosphate ring and generates the quaternary ammonium phosphorylcholine zwitterion. Crystallization or selective precipitation must remove amine, salts, solvent and unreacted cyclic species without prolonged heating. Final drying is performed gently, followed by controlled addition or retention of an inhibitor such as MEHQ when the agreed grade requires it.

2.3 Core Application Matrix

• Ophthalmic and hydrogel materials: MPC copolymers can increase surface wettability and resist tear-protein deposition in contact-lens materials. Related networks support wound dressings and highly hydrated medical hydrogels. Developers must demonstrate optical, mechanical, sterilization and biological performance in the final formulation rather than extrapolate from monomer literature.
• Blood-contacting device coatings: Catheters, guidewires, blood-handling components and drug-eluting stent platforms use MPC-containing coatings to create lubricious, antifouling interfaces. Coating integrity, particulate generation, drug-release interaction and residual monomer are device-specific risks requiring validated process controls and biological evaluation.
• Delivery and surface-engineering platforms: MPC blocks can be incorporated into micelles, nanoparticles, membranes and tissue-engineering surfaces. Nonmedical applications include antifouling interfaces and ion-conductive gels. Supply agreements should distinguish medical-device development material from research material and expressly define whether endotoxin, bioburden or animal-origin statements are required.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is driven by premium silicone-hydrogel lenses, low-fouling disposable devices, blood-contacting surfaces and next-generation hydrogel systems. Device companies are moving from catalog purchases toward application-specific qualification because small variations in inhibitor, moisture or ionic impurities can alter graft density and coating performance. The strongest growth opportunity is therefore not undifferentiated tonnage, but reproducible lots supported by analytical methods, long-term stability data and regulatory access packages.

3.2 Capacity Distribution and Export Flows

China and Japan anchor much of the specialized monomer know-how and commercial supply, while the EU and United States contain major biomaterial formulators, coating developers and regulated-device customers. Export flows are typically small-volume, high-value and temperature managed. Buyers should qualify more than one synthetic site where possible, yet a second source cannot be considered interchangeable until polymerization response, impurity profile and device performance have been bridged.

3.3 Market Bifurcation and Pricing Dynamics

Research grade is generally sold in gram-scale packs with identity and broad purity data. Medical-device grade is a contractual quality category, not a universal compendial standard: its premium reflects tighter water and inhibitor ranges, endotoxin or bioburden controls, validated test methods, extended change notification, audit rights and document retention. Price also reflects cold storage, short campaign lengths and low recovery during ionic purification. Comparing offers only by HPLC area percent obscures these cost drivers.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

MPC is a chemical monomer, not an independently approved device. REACH and TSCA obligations apply to chemical manufacture and import, while medical-device requirements attach to the final material and intended use. Buyers must verify inventory or registration status, annual tonnage, importer role and current supplier SDS. A GHS skin-sensitization classification such as Skin Sensitization Category 1 and H317 appears in some supplier dossiers, but classification must be determined from the marketed substance and jurisdiction-specific evidence.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH and CLP: EU importers should confirm whether MPC is registered, exempt at their tonnage or covered by an only-representative arrangement, and ensure that use descriptors include monomer and biomaterial manufacture. CLP classification, labeling and SDS language must follow the supplier's actual dossier. Residual inhibitor and stabilizing conditions should be disclosed because they affect both safe handling and downstream polymerization.
• EU MDR 2017/745: Device manufacturers must address chemical and biological safety under Annex I, with material characterization, toxicological evaluation, extractables and leachables, and biological endpoints selected through an ISO 10993 risk-management process. MPC supply documentation should support traceability and change assessment. Compliance with a monomer specification does not by itself confer CE conformity or establish clinical performance.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA and workplace compliance: US importers must confirm active TSCA Inventory status or an applicable exemption before commercial import. OSHA Hazard Communication documentation should reflect the lot and supplied form. Polymer exemptions, where relevant to a downstream MPC copolymer, do not automatically exempt the monomer transaction, and R&D exemptions require controlled purpose and records.
• FDA device documentation and MAF: A supplier may maintain a device Master File, commonly called an MAF, containing confidential chemistry, manufacturing and controls information and authorize FDA review by letter of authorization. ISO 13485 certification strengthens quality-system alignment, while ISO 10993 data and USP Class VI testing can support a program. Neither USP Class VI nor a raw-material test substitutes for biological evaluation of the finished device.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

MPC manufacturing uses phosphorus reagents, chlorinated or polar aprotic solvents in some routes, amines and energy-intensive purification. Environmental review should cover acidic off-gas capture, salt-rich aqueous waste, solvent recovery, worker exposure and polymer-contaminated equipment cleaning. ISO 14001 data, emissions permits and waste-contractor records are increasingly relevant in supplier audits, particularly when a medical customer must document Scope 3 emissions and continuity risks.

5.1 Carbon Footprint and Circular Economy

Process intensification can improve heat transfer during cyclic phosphate formation and reduce off-specification polymerized material. Solvent recovery, low-temperature drying efficiency and campaign planning are practical carbon levers. Suppliers should report cradle-to-gate boundaries, electricity mix, recovered-solvent allocation and waste assumptions rather than a single unexplained carbon number. PPWR-driven packaging reduction must be balanced against moisture protection and cold-chain integrity.

5.2 Sustainable Sourcing and Traceability

Traceability should extend to hydroxyethyl methacrylate, the cyclic phosphorus reagent, trimethylamine, solvents and inhibitor. Medical programs benefit from supplier-change notification, retained samples and chain-of-custody records. Buyers should also examine phosphorus-effluent controls, amine capture and mass balance. Animal-origin-free statements may be requested for regulated biomaterials, but they require documented raw-material review rather than assumptions based on the synthetic structure.

VI. Supply Chain Resilience and Export Logistics

MPC's principal logistics threat is quality drift rather than bulk freight availability. Warm excursions can accelerate inhibitor loss or oligomer formation, while repeated opening rapidly increases water. A lane qualification should define dispatch temperature, maximum excursion, light protection, data-logger placement, customs contingencies and the testing required after deviation. Safety classification and transport status must always follow the current lot-specific SDS.

6.1 Packaging Standards and Moisture/Contamination Control

• Primary containment: Use light-resistant, tightly sealed compatible bottles or lined containers under dry nitrogen, with qualified desiccant and tamper evidence where appropriate. Small unit sizes reduce freeze-thaw or open-close cycles. Packaging qualification should assess water-vapor transmission, extractables and seal performance at the intended low storage temperature.
• Inhibitor and condition records: The label and CoA should state inhibitor identity and measured or specified concentration, storage range, retest date and whether the material is inhibitor-free. Inhibitor-free MPC presents a higher polymerization risk and requires a customer-approved handling plan; nitrogen blanketing does not eliminate the need for validated stabilization.

6.2 Dangerous Goods Identification and Transit Protocols

Many supplier SDSs treat stabilized solid MPC as not regulated as dangerous goods under ADR, IMDG or IATA, although it may carry a skin-sensitization warning. That conclusion is product-specific. Refrigerated or frozen shipment is an operational quality control, not automatically a dangerous-goods classification. Avoid dry ice in sealed primary packaging, segregate from heat and radical initiators, and use temperature evidence for disposition after any delay.

VII. Enterprise Global Expansion Strategy Guide

A scalable MPC sourcing program aligns monomer controls with the customer's polymer process and device dossier. The supplier and buyer should jointly identify attributes that affect coating or gel performance, create a comparability protocol for changes, and maintain regulatory evidence by market. This approach prevents a nominally conforming lot from creating costly downstream revalidation.

1. Segment grades by intended use: Keep research grade and medical-device development grade under distinct specifications, labels, quality agreements and release pathways. For medical programs, define endotoxin, bioburden, trace metals, inhibitor, water and change-control expectations and state clearly that the monomer is not a finished medical product.
2. Build a regulatory bridge: Map ISO 10993 evidence, USP Class VI data where used, ISO 13485 controls, EU MDR technical-document inputs and FDA MAF references. Identify which tests belong to the supplier and which remain the device manufacturer's responsibility. Review REACH and TSCA status before commercial scale-up.
3. Validate the cold, dry lane: Conduct transport simulations and seasonal lane studies, establish excursion rules, and qualify backup couriers and customs brokers. Include arrival testing for water, appearance and soluble oligomers. Maintain a second-source plan based on functional polymerization comparability, not solely on matching monomer assay.

VIII. Conclusion

MPC translates a cell-membrane-inspired phosphorylcholine group into a versatile polymerizable monomer. Its value in contact lenses, catheters, stent coatings, blood-contacting systems, wound dressings and hydrogels rests on controlled hydration and antifouling behavior. Real commercial differentiation comes from stable chemistry, reproducible inhibitor and water control, and documentation that allows device developers to understand and manage material risk.

For 2026 sourcing, buyers should combine chemical compliance, ISO-aligned quality systems, device-specific biological evaluation support and robust low-temperature logistics. Neither MPC nor an MPC-containing polymer should be represented as clinically safe solely because of its structure or a supplier test. Final claims require the finished device's complete technical, biological and clinical evidence, reviewed under the applicable jurisdiction.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 2-Methacryloyloxyethyl phosphorylcholine (MPC) Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 2-Methacryloyloxyethyl phosphorylcholine (MPC) supply chain:

• China specialty-monomer ecosystem: Chinese producers combine phosphorus chemistry, methacrylate processing and scale-up capacity, supplying research and device-development programs. Qualification should focus on site-level quality systems, inhibitor control, batch traceability, export temperature capability and evidence that claimed medical grades are segregated from general industrial production.
• Japan biomaterials ecosystem: Japan has longstanding phosphorylcholine-polymer know-how linked to ophthalmic materials, precision coatings and high-value medical-device development. The ecosystem emphasizes intellectual property, narrow specifications and application collaboration. Buyers should clarify licensing, regional supply rights, audit access and continuity arrangements early in development.
• EU and US device-development ecosystem: European and American formulators, polymer specialists, contract coaters and regulated-device manufacturers create demand for highly documented MPC. Their programs prioritize ISO 10993 strategy, ISO 13485 controls, MAF or technical-file support, extractables assessment and validated cold-chain distribution rather than commodity-scale pricing.